Abbott announces superior long-term efficacy of Humira
19 September 2008 00:00 in Pharmaceutical Company Product News
Abbott has announced the results of a new analysis that shows the superiority of continuous treatment with Humira (adalimumab) compared to the interruption of therapy in patients with psoriasis.
According to the year-long Reveal study sub-analysis presented at the congress of the European Academy of Dermatology and Venereology in Paris, the interruption of therapy had a negative effect on PASI.
Furthermore, additional analysis showed the compound to effectively treat adult patients with moderate to severe forms of psoriasis, regardless of recent systemic therapy, diagnosis of psoriatic arthritis, duration of disease or age.
The company said at 16 weeks of treatment, 71 per cent of patients on Humira showed a PASI response, compared to 6.5 per cent of patients given a placebo, with similar results observed in the above subgroups.
Rebecca Hoffman, divisional vice-president of immunology at Abbott, said: "These studies pertain to the efficacy of Humira and provide further evidence for physicians and patients regarding Humira's ability to clear the frequently-painful skin lesions associated with psoriasis."
She added that the company is dedicated to ongoing research into the best use of the compound in psoriasis and other therapeutic areas.
Earlier this week, Humira was approved in the European Union for the treatment of polyarticular juvenile idiopathic arthritis.
Other news stories from 19/09/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency